## Annabelle A Okada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6630834/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multicenter Study of Infliximab for Refractory Uveoretinitis in Behçet Disease. JAMA Ophthalmology, 2012, 130, 592.	2.4	149
2	Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR. Advances in Therapy, 2020, 37, 1173-1187.	2.9	144
3	One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy. Ophthalmology, 2015, 122, 1866-1872.	5.2	114
4	Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 617-624.	5.2	106
5	Evaluation of the Long-Term Efficacy and Safety of Infliximab Treatment for Uveitis in Behçet's Disease. Ophthalmology, 2014, 121, 1877-1884.	5.2	103
6	Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1149-1156.	1.9	97
7	Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy. British Journal of Ophthalmology, 2011, 95, 1245-1250.	3.9	67
8	Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Japanese Journal of Ophthalmology, 2021, 65, 184-190.	1.9	52
9	Behçet's disease: general concepts and recent advances. Current Opinion in Ophthalmology, 2006, 17, 551-556.	2.9	40
10	Pachychoroid: current concepts on clinical features and pathogenesis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1385-1400.	1.9	40
11	Cystoid Macular Edema in Uveitis. Developments in Ophthalmology, 2010, 47, 136-147.	0.1	37
12	Epidemiology of Macular Edema in Uveitis. Ocular Immunology and Inflammation, 2019, 27, 169-180.	1.8	36
13	Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study. Ocular Immunology and Inflammation, 2017, 25, 46-51.	1.8	33
14	Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration. Ophthalmology Retina, 2020, 4, 767-776.	2.4	30
15	Serum levels of candidate microRNA diagnostic markers differ among the stages of non‑small‑cell lung cancer. Oncology Letters, 2018, 16, 6643-6651.	1.8	26
16	One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration. Ophthalmologica, 2017, 237, 139-144.	1.9	24
17	Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Japanese Journal of Ophthalmology, 2018, 62, 584-591.	1.9	16
18	Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 567-574.	1.9	14

#	Article	IF	CITATIONS
19	Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with BehA§et's disease. British Journal of Ophthalmology, 2021, 105, 1525-1533.	3.9	7
20	Clinical features and visual outcomes of ocular sarcoidosis at a tertiary referral center in Tokyo. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 3357-3363.	1.9	4
21	Association Study of ARMC9 Gene Variants with Vogt-Koyanagi-Harada Disease in Japanese Patients. Ocular Immunology and Inflammation, 2019, 27, 699-705.	1.8	3
22	Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup. Advances in Therapy, 2022, 39, 2984-2998.	2.9	3
23	Prognostic value of subfoveal choroidal thickness in newâ€onset acute <scp>Vogtâ€Koyanagiâ€Harada</scp> disease. Clinical and Experimental Ophthalmology, 2022, , .	2.6	0